Christopher J Hale

US Patent:

8134047, Mar 13, 2012

Filed:

Mar 9, 2009

Appl. No.:

12/400727

Inventors:

Jennifer L. Stonaker - Fremont CA, US
Christopher J. Hale - El Cerrito CA, US
Jay B. Hollick - Berkeley CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 15/82
A01H 5/10

US Classification:

800286, 800285, 800298, 8003201

Abstract:

Maize plants with reduced gene silencing are disclosed.

US Patent:

20220411433, Dec 29, 2022

Filed:

Nov 19, 2021

Appl. No.:

17/531039

Inventors:

- South San Francisco CA, US
Javier de Vicente Fidalgo - Foster City CA, US
Anthony A. Estrada - Danville CA, US
Jianwen A. Feng - San Mateo CA, US
Brian M. Fox - Redwood City CA, US
Christopher R.H. Hale - South San Francisco CA, US
Katrina W. Lexa - San Francisco CA, US
Maksim Osipov - Redwood City CA, US
Travis Remarchuk - South San Francisco CA, US
Zachary K. Sweeney - Redwood City CA, US

International Classification:

C07D 491/048
C07C 235/22
C07D 207/27
C07D 233/36
C07D 233/42
C07D 233/61
C07D 233/64
C07D 249/04
C07D 249/08
C07D 257/04
C07D 261/04
C07D 261/08
C07D 263/32
C07D 263/38
C07D 263/56
C07D 271/06
C07D 271/10
C07D 291/04
C07D 401/12
C07D 403/04
C07D 403/12
C07D 413/04
C07D 413/06
C07D 413/12
C07D 417/04
C07D 471/04
C07D 487/04

Abstract:

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

US Patent:

20210322737, Oct 21, 2021

Filed:

Apr 13, 2021

Appl. No.:

17/229587

Inventors:

- Oakland CA, US
Devin K. Binder - Irvine CA, US
Christopher Hale - Palm Desert CA, US
Jennifer Yonan - Irvine CA, US

International Classification:

A61M 27/00

Abstract:

A continuous-flow system for the treatment of edema in an injured central nervous system (CNS) tissue, including: a reversibly implantable device having: an inflow pathway, an outflow pathway, and a fluid flow pathway connecting the first outlet of the inflow pathway and the second inlet of the outflow pathway, wherein the fluid flow pathway includes a semi-permeable membrane; a first reservoir; a fluid-driving apparatus; a second reservoir; and a plurality of fluid flow conduits that fluidically connect the first reservoir, the fluid-driving apparatus, the second reservoir, and the reversibly implantable device; wherein the reversibly implantable device is configured to allow direct contact between the semi-permeable membrane and at least a portion of the injured CNS tissue; wherein the system is configured to contain a solution that pass through the fluid flow pathway and induces osmotic flow of water from the injured CNS tissue across the semipermeable membrane and into the solution, thereby decreasing swelling of the tissue. Also disclosed are related methods for removing water from a traumatically injured central nervous system (CNS) tissue in a subject.

US Patent:

20210147435, May 20, 2021

Filed:

Aug 8, 2018

Appl. No.:

16/637718

Inventors:

- South San Francisco CA, US
Javier de Vicente Fidalgo - Foster City CA, US
Anthony A. Estrada - San Mateo CA, US
Jianwen A. Feng - San Mateo CA, US
Brian M. Fox - Brisbane CA, US
Christopher R.H. Hale - South San Francisco CA, US
Katrina W. Lexa - San Francisco CA, US
Maksim Osipov - Redwood City CA, US
Travis Remarchuk - South San Francisco CA, US
Zachary K. Sweeney - Redwood City CA, US

International Classification:

C07D 491/048
C07D 413/04
C07D 271/10
C07D 249/04
C07D 261/04
C07D 261/08
C07D 263/32
C07C 235/22
C07D 249/08
C07D 233/61
C07D 413/12
C07D 487/04
C07D 471/04
C07D 413/06
C07D 403/12
C07D 401/12
C07D 271/06
C07D 263/38
C07D 207/27
C07D 233/42
C07D 233/36
C07D 403/04
C07D 263/56
C07D 233/64
C07D 257/04
C07D 417/04
C07D 291/04

Abstract:

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

US Patent:

20200223866, Jul 16, 2020

Filed:

Nov 18, 2019

Appl. No.:

16/686912

Inventors:

- Foster City CA, US
John Enquist, JR. - San Mateo CA, US
Nolan Griggs - San Mateo CA, US
Christopher Hale - San Francisco CA, US
Norihiro Ikemoto - South Plainfield NJ, US
Katie Ann Keaton - Niwot CO, US
Matt Kraft - Belmont CA, US
Scott E. Lazerwith - Burlingame CA, US
Michel Leeman - Fairfield NJ, US
Zhihui Peng - Niantic CT, US
Kate Schrier - Redwood City CA, US
Jonathan Trinidad - Fremont CA, US
Jochem Van Herpt - Fairfield NJ, US
Andrew W. Waltman - Kalamazoo MI, US

International Classification:

C07D 498/14
C07D 319/06
C07C 237/20
C07D 213/82
C07D 309/40
C07C 235/80
C07D 498/22
C07C 231/02
C07C 231/12

Abstract:

Methods of making compounds of Formula I are disclosed:

US Patent:

20200087319, Mar 19, 2020

Filed:

Nov 14, 2019

Appl. No.:

16/684340

Inventors:

- South San Francisco CA, US
Anthony A. Estrada - South San Francisco CA, US
Jianwen A. Feng - South San Francisco CA, US
Brian Fox - South San Francisco CA, US
Cinzia Maria Francini - Verona, IT
Christopher R.H. Hale - South San Francisco CA, US
Cheng Hu - South San Francisco CA, US
Colin Philip Leslie - Verona, IT
Maksim Osipov - South San Francisco CA, US
Elena Serra - Verona, IT
Zachary K. Sweeney - South San Francisco CA, US
Arun Thottumkara - South San Francisco CA, US

Assignee:

Denali Therapeutics Inc. - South San Francisco CA

International Classification:

C07D 498/04
C07D 223/16
C07D 267/14
C07D 413/14
C07D 267/04
C07D 519/00

Abstract:

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

US Patent:

20190250824, Aug 15, 2019

Filed:

Apr 26, 2019

Appl. No.:

16/396432

Inventors:

- Boise ID, US
Ashutosh Malshe - Fremont CA, US
Sampath K. Ratnam - Boise ID, US
Peter Feeley - Boise ID, US
Michael G. Miller - Boise ID, US
Christopher S. Hale - Boise ID, US
Renato C. Padilla - Boise ID, US

International Classification:

G06F 3/06
G06F 12/0888
G06F 12/0893
G06F 12/02
G06F 11/34

Abstract:

Memory devices are disclosed. A memory device may include main memory and a hybrid cache. The hybrid cache includes a dynamic cache including x-level cell (XLC) blocks of non-volatile memory cells shared between the dynamic cache and the main memory. The hybrid cache further includes a static cache including single-level cell (SLC) blocks of non-volatile memory cells. The memory device further includes a memory controller configured to disable at least one of the static cache and the dynamic cache responsive to a workload of the hybrid cache relative to a Total Bytes Written (TBW) Spec for the memory device. Methods of operating a memory device and an electronic system are also described.

US Patent:

20190065365, Feb 28, 2019

Filed:

Aug 31, 2017

Appl. No.:

15/693153

Inventors:

- Boise ID, US
Kishore Kumar Muchherla - Fremont CA, US
Peter Feeley - Boise ID, US
Ashutosh Malshe - Fremont CA, US
Daniel J. Hubbard - Boise ID, US
Christopher S. Hale - Boise ID, US
Kevin R. Brandt - Boise ID, US
Sampath K. Ratnam - Boise ID, US

International Classification:

G06F 12/02
G06F 12/0891

Abstract:

A memory system includes: a memory array including a plurality of memory cells, the plurality of memory cells including a plurality of cache memory cells; and a controller coupled to the memory array, the controller configured to: track usage of a first subset of the plurality of cache memory cells operating in a single-level cell (SLC) mode, wherein the tracking includes monitoring for an idle time event; and designate a storage mode for a second subset of the plurality of cache memory cells based on the tracked usage of the first subset, wherein the storage mode determines a storage density to be used for data writes.